Abstract
No public abstract is available from the verified source records.
Ximena Maria Muresan, Adrian Bogdan Tigu, Andrei Roman, Arianna Romani
Abstract
Authors
Institutions
No ROR-resolved institution is linked to this work yet.
Provenance
crossref
Confidence 100%
pubmed
Confidence 98%
europepmc
Confidence 96%
unpaywall
Confidence 95%
doaj
Confidence 92%
datacite
Confidence 0%
No local reference links have been materialized yet.
No local citing links have been materialized yet.
Biomarkers and 3D models predicting response to immune checkpoint blockade in head and neck cancer
10.3892/ijo.2022.5378 · 2022
A comprehensive review of immune checkpoint inhibitors for cancer treatment
10.1016/j.intimp.2024.113365 · 2024
Improving natural killer cell cancer immunotherapy
10.1097/mot.0000000000000243 · 2015
Targeting menin in lysine methyltransferase 2A/nucleophosmin-mutated leukemia: a novel strategy from epigenetic dysregulation to clinical therapy
10.3892/ol.2025.15265 · 2025
Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries
10.3322/caac.21834 · 2024
Role and therapeutic targeting of the PI3K/Akt/mTOR signaling pathway in skin cancer: a review of current status and future trends on natural and synthetic agents therapy
10.3390/cells8080803 · 2019
Does research from clinical trials in metastatic hormone-sensitive prostate cancer treatment translate into access to treatments for patients in the “real world”? A systematic review
10.1016/j.euo.2023.05.002 · 2023
BRD4 and cancer: going beyond transcriptional regulation
10.1186/s12943-018-0915-9 · 2018
Two decades of a protooncogene TBL1XR1: from a transcription modulator to cancer therapeutic target
10.3389/fonc.2024.1309687 · 2024
Hallmarks of cancer: new dimensions
10.1158/2159-8290.cd-21-1059 · 2022
Mechanisms and management of 3rd-generation EGFR-TKI resistance in advanced non-small cell lung cancer
10.3892/ijo.2021.5270 · 2021
Pediatric acute lymphoblastic leukemia
10.3324/haematol.2020.247031 · 2020
Proteolysis-targeting chimera (PROTAC) for targeted protein degradation and cancer therapy
10.1186/s13045-020-00885-3 · 2020
Resistance to antibody-drug conjugates: a review
10.1016/j.apsb.2024.12.036 · 2024
Precision medicine review: rare driver mutations and their biophysical classification
10.1007/s12551-018-0496-2 · 2019
Chronic myeloid leukemia, from pathophysiology to treatment-free remission: a narrative literature review
10.2147/jbm.s382090 · 2023
The promise of targeted therapy: cancer drugs become more specific
10.3949/ccjm.71.7.551 · 2004
Chimeric antigen receptor T-cell therapy in cancer: a critical review
10.2174/2589977515666230220092125 · 2023
Synthetic lethal and resistance interactions with BET bromodomain inhibitors in triple-negative breast cancer
10.1016/j.molcel.2020.04.027 · 2020
Development, efficacy and side effects of antibody-drug conjugates for cancer therapy
10.3892/mco.2023.2643 · 2023
Advantages and research progress of three-dimensional culture systems for lung cancer drug screening
10.3892/ol.2026.15702 · 2026
Safety and efficacy of anaplastic lymphoma kinase tyrosine kinase inhibitors in non-small cell lung cancer
10.3892/or.2020.7851 · 2020
Molecular mechanisms of platinum-based chemotherapy resistance in ovarian cancer
10.3892/or.2022.8293 · 2022
Application of multivalent aptamers in tumor diagnosis, analysis and therapy
10.3892/ol.2025.15071 · 2025
T lymphocyte-related immune response and immunotherapy in gastric cancer
10.3892/ol.2024.14670 · 2024
No additional external references are available.